Prader-Willi Syndrome: Metabolic aspects related to growth hormone treatment;Síndrome de Prader-Willi: Aspectos metabólicos associados ao tratamento com hormônio de crescimento

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 1, 2007, Pages 92-98

  Kuo, Jack Y ^a,b   Ditchekenian, Vaê ^a   Manna, Thaís D ^a   Kuperman, Hilton ^a   Damiani, Durval ^a   Setian, Nuvarte ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Body composition; Growth hormone; Obesity; Prader Willi syndrome

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADIPOCYTE; ADIPOSE TISSUE; ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY MASS; CASE REPORT; CHILD; DRUG EFFECT; FEMALE; HUMAN; LIPID METABOLISM; MALE; METABOLISM; PHYSIOLOGY; PRADER WILLI SYNDROME; SKINFOLD THICKNESS; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE; ADOLESCENT; BODY COMPOSITION; BODY MASS INDEX; CHILD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MALE; PRADER-WILLI SYNDROME; SKINFOLD THICKNESS; WEIGHT GAIN;

EID: 34247109629     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000100015     Document Type: Article

References (45)

1. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 1956;86:1260-1.
2. Gillessen-Kaesbach G, Gross S, Kaya-Westerloh S, Passarge E, Horsthemke B. DNA methylation based testing of 450 patients suspected of having Prader-Willi syndrome. J Med Genet 1995;32:88-92.
3. Holm V, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitmann BYGF. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402.
4. Cassidy SB. Prader-Willi syndrome. J Med Genet 1997;34:917-23.
5. Greenswag L. Adults with Prader-Willi syndrome. A survey of 232 cases. Dev Med Child Neurol 1987;29:145-52.
6. Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G. Peculiar body composition in patients with Prader-Willi syndrome. Am J Clin Nutr 1997;65:1369-74.
7. Nelson RA, Huse DM, Holman RT. Nutrition, metabolism, body composition and response to the Ketogenic diet in Prader-Willi Syndrome. In: Holm VA, Sulzbacher S, Pipes PL (eds.). Prader-Willi Syndrome, chapt 8. University Baltimore: Park Press, 1981. pp. 105-20.
8. Selikowitz M, Summan J, Pendergast A, Wright S. Fenfluramine in Prader-Willi Syndrome: a double-blind, placebo-controlled trial. Arch Dis Child 1990;65:112-4.
9. Marinari G, Gianella E, Adami G, Gandllo P, Scopinoro N. Long-term results of bileopancreatic diversion in subjects with Prader-Willi Syndrome Obes Surg 1996;6:303-4.
10. Soper RT, Mason EE, Printen KJ, Zellweger H. Surgical treatment of morbid obesity in Prader-Willi Syndrome. In: Holm VA, Sulzbacher S, Pipes PL (eds). Prader-Willi Syndrome. Baltimore: University Park Press, 1981. pp. 121-31.
11. Nam SY, Marcus C. Growth hormone and adipocyte function in obesity. Horm Res 2000;53(suppl):87-97.
12. th ed. Philadelphia: Saunders, 1998, pp. 1102-3.
13. Dietz J, Schwartz J. Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes. Metabolism 1991;40(8):800-6.
14. Ottosson M, Vikman-Adolfsson K, Enerback S, Elander A, Bjorntorp P, Eden S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995;80(3):934-41.
15. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82(3):727-34.
16. Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22(6):787-99.
17. Hauffa BP. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr Suppl 1997;423:63-5.
18. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000;137:42-9.
19. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87(4):1581-5.
20. Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2003;16(2):155-62.
21. Hoybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004;14(1):1-15.
22. Frisancho A. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press, 1993. p. 32.
23. Rolland-Cachera MF. Body composition during adolescence: methods, limitations and determinations. Horm Res 1993;39:25.
24. EPI INFO 2000 Division of Nutrition. Center for Chronic Disease Prevention and Health Promotion. Centers for Disease Control and Prevention 1600 Clifton Road NE, MS A08. Atlanta, GA 30333 U.S.A. Nutrition Unit. World Health Organization. 1211 Geneva 27. Switzerland (www.CDC.com)
25. th ed. Philadelphia: Saunders, 1998. pp. 1471-3.
26. Greulich WW, Pyle ST. Radiological Skeletal Development of the Hand and Wrist. Stanford: Stanford University Press, 1959.
27. Corrias A, Bellone J, Beccaria L, Bosio L, Trifiro G, Livieri C, et al. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000;23:84-9.
28. Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996;3:393-9.
29. avies PSW, Evens S, Broomhead S, Clough H, Day JME, Laidlaw A, et al. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome. Arch Dis Child 1998;78:474-6.
30. Carrel AL, Allen DB. Effects of growth hormone on body composition and bone metabolism. Endocrine 2000;12(2):163-72.
31. Eiholzer U, Blum WF, Molinari L. Body fat determined by skin-fold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. J Pediatr 1999;134:222-5.
32. Rosenbaum M, Gerner J, Leibel R. Effects of systemic (GH) administration on regional adipose tissue distribution in GH deficient children. J Clin Endocrinol Metab 1989;69:1274-81.
33. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83:107-16.
34. Davies PSW, Joughin C. Assessment of body composition in the Prade-Willi syndrome. Am J Med Genet 1992;44:75-8.
35. Lee PD, Hwu K, Henson H, Brown BT, Bricker JT, Leblanc AD, et al. Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy. Basic Life Sci 1993;60:201-5.
36. Fomon SJ, Hasche F, Ziegler EE, Nelson SF. Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982;35:1169-75.
37. th ed. Philadelphia: Saunders, 1998. p. 1062.
38. Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Pediatr Suppl 1997;423:50-4.
39. Miller L, Angulo M, Price D, Taneja S. MR of the pituitary in patients with Prader-Willi syndrome: size determinations and imaging findings. Pediatr Radiol 1996;26:43-7.
40. Van Mil EG, Westerterp KR, Kester AD, Curfs LM, Gerver WJ, Schrander-Stumpel CT, et al. Activity related energy expenditure in children and adolescents wit Prader-Willi syndrome. Int Obes Relat Metab Disord 2000;24:429-34.
41. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, Lafranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88(5):2206-12.
42. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992;89(15):6983-7.
43. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish Growth Hormone Advisory Group. Acta Paediatr Scand Suppl 1999;433:109-11.
44. Park MJ, Kim HS, Kang JH, Kim DH, Chung CY. Serum levels of insulin-like growth factor (IGF)-I, free IGF-I, IGF binding protein (IGFBP)-I, IGFBP-3 and insulin in obese children. J Pediatr Endocrinol Metab 1999;12:139-44.
45. National Cholesterol Education Program - Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992; 89:525.